Sự tham gia của thận trong bệnh viêm ruột ở trẻ em

de Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13–27 Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806 Ott C, Scholmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10:585–595 Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F (2019) The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 13:541–554 Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819–4831 Ambruzs JM, Larsen CP (2018) Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am 44:699–714 Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S (2011) Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 17:1034–1045 Ricart E, Sandborn WJ (2003) Extraintestinal manifestations of inflamamtory bowel disease. In: Cohen RD (ed) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Totowa Ambruzs JM, Walker PD, Larsen CP (2014) The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 9:265–270 McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89:835–841 Bianchi L, Gaiani F, Bizzarri B, Minelli R, Cortegoso Valdivia P, Leandro G, Di Mario F, De’ Angelis GL, Ruberto C (2018) Renal lithiasis and inflammatory bowel diseases, an update on pediatric population. Acta Biomed 89:76–80 Parks JH, Worcester EM, O’Connor RC, Coe FL (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63:255–265 Katsanos K, Tsianos EV (2002) The kidneys in inflammatory bowel disease. Ann Gastroenterol 15:41–52 Ganji-Arjenaki M, Nasri H, Rafieian-Kopaei M (2017) Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. J Nephropathol 6:264–269 Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7:371–379 Kane S (2006) Urogenital complications of Crohn’s disease. Am J Gastroenterol 101(12 Suppl):S640–S643 Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT (1998) Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 93:504–514 Johnson E, Vu L, Matarese LE (2018) Bacteria, bones, and stones: managing complications of short bowel syndrome. Nutr Clin Pract 33:454–466 Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF (2001) Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 15:363–369 Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ (2001) Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 15:1131–1137 Kreisel W, Wolf LM, Grotz W, Grieshaber M (1996) Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 8:461–468 Velciov S, Gluhovschi G, Sporea I, Trandafirescu V, Petrica L, Bozdog G, Gluhovschi C, Bob F, Gădălean F, Buzaş R, Bobu M, Voicu L (2011) Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study. Rom J Intern Med 49:113–120 Corica D, Romano C (2015) Renal involvement in inflammatory bowel diseases. J Crohns Colitis 10:226–235 Filiopoulos V, Trompouki S, Hadjiyannakos D, Paraskevakou H, Kamperoglou D, Vlassopoulos D (2010) IgA nephropathy in association with Crohn’s disease: a case report and brief review of the literature. Ren Fail 32:523–527 Shaer AJ, Stewart LR, Cheek DE, Hurray D, Self SE (2003) IgA antiglomerular basement membrane nephritis associated with Crohn’s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 41:1097–1109 Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196 Freedman BI, Spray BJ, Heise ER (1994) HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am J Kidney Dis 23:352–357 Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ (1999) HLA-DR and -DQ phenotypes in inflammatory bowel disease: A meta-analysis. Gut 45:395–401 Coppo R (2018) The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol 33:53–61 Rodrigues JC, Haas M, Reich HN (2017) IgA Nephropathy epidemiology of IgA nephropathy. Clin J Am Soc Nephrol 12:677–686 Suárez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC (2017) T cells and autoimmune kidney disease. Nat Rev Nephrol 13:329–343 Ridder RM, Kreth HW, Kiss E, Gröne HJ, Gordjani N (2005) Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol 20:1349–1351 Jang HM, Baek HS, Kim JE, Kim JY, Lee YH, Cho HY, Choe YH, Kang B, Choe BH, Choi BS, Cho MH (2018) Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 61:327–331 Marcus SB, Brown JB, Melin-Aldana H, Strople JA (2008) Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in Children. J Pediatr Gastroenterol Nutr 46:338–341 Bastard JP, Fellahi S, Regeniter A, Capeau J, Ronco P, Plaisier E (2019) Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice? Clin Biochem 65:1–6 Muhammad HSS, Peters C, Casserly LF, Dorman AM, Watts M (2010) Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure. Clin Nephrol 73:250–252 Elloumi H, Ben Slama A, Arfaoui D, Ghouma M, Sfar S, Ajmi S (2006) Renal amyloidosis complicating Crohn’s disease: report of two cases and review of literature. Tunis Med 84:253–255 Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SD, Wechalekar AD, Gilbertson JA, Rowczenio D, Hawkins PN, Lachmann HJ (2013) Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 58:1689–1697 Papa R, Lachmann HJ (2018) Secondary, AA, Amyloidosis. Rheum Dis Clin North Am 44:585–603 Kirschner BS, Samowitz WS (1986) Secondary amyloidosis in Crohn’s disease of childhood. J Pediatr Gastroenterol Nutr 5:816–821 Cucino C, Sonnenberg A (2001) The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn’s disease. Am J Gastroenterol 96:2107–2112 Ebert EC, Nagar M, (2008) Gastrointestinal Manifestations of Amyloidosis. Am J Gastroenterol 103(3):776–787 Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM, European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (2012) Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 55:340–361 Christensen LA, Fallingborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, Rasmussen SN (1994) Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 8:289–294 Muller AF, Stevens PE, Mcintyre AS, Ellison H, Logan RF (2005) Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 21:1217–1224 Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J (2008) Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol 31:477–484 de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH (2005) 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 11:972–976 Uslu N, Demir H, Saltik-Temizel IN, Topaloğlu R, Gürakan F, Yüce A (2007) Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci 52:2926–2929 Co ML, Gorospe EC (2013) Pediatric case of mesalazine-induced interstitial nephritis with literature review. Pediatr Int 55:385–387 Bir K, Herzenberg AM, Carette S (2006) Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener’s granulomatosis. J Rheumatol 33:185–187 Meys E, Devogelaer JP, Geubel A, Rahier J, Nagant de Deuxchaisnes C (1992) Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. J Rheumatol 19:807–809 Danese S, Vuitton L, Peyrin-Biroulet L (2015) Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 12:537–545 Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406 Haake H, Koneke J, Amann K, vom Dahl J, Janssen U (2007) Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin (Munich) 102:852–857 Neale TJ, Rüger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A, Murray-McIntosh RP, Kitching AR (1995) Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 146:1444–1454 Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390 Saka Y, Taniguchi Y, Nagahara Y, Yamashita R, Karasawa M, Naruse T, Watanabe Y (2017) Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis. Lupus 26:447–448 Baumgart DC, MacDonald JK, Feagan B (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 3:CD007216 Hosoi K, Arai K, Matsuoka K, Shimizu H, Kamei K, Nakazawa A, Shimizu T, Tang J, Ito S (2017) Prolonged tacrolimus for pediatric gastrointestinal disorder: double-edged sword? Pediatr Int 59:588–592 Watson S, Pensabene L, Mitchell P, Bousvaros A (2011) Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 17:22–29 Baumgart DC, Wiedenmann B, Dignass AU (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17:1273–1281 Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66:839–851 Bailly E, Von Tokarski F, Beau-Salinas F, Picon L, Miquelestorena-Standley E, Rousseau G, Jonville-Bera AP, Halimi JM (2018) Interstitial nephritis secondary to vedolizumab treatment in crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 71:142–145